Glucocorticoid Receptor Gene Polymorphisms and Lung Disease in Cystic Fibrosis
Author Information
Author(s): Harriet Corvol, Nadia Nathan, Celine Charlier, Katarina Chadelat, Philippe Le Rouzic, Olivier Tabary, Brigitte Fauroux, Alexandra Henrion-Caude, Josue Feingold, Pierre-Yves Boelle, Annick Clement
Primary Institution: Université Pierre et Marie Curie-Paris6
Hypothesis
Glucocorticoid receptor gene polymorphisms may affect glucocorticoid sensitivity in cystic fibrosis and contribute to variations in the inflammatory response.
Conclusion
The BclI polymorphism may modulate the inflammatory burden in the CF lung and influence progression of lung function.
Supporting Evidence
- A significant association was found between BclI genotypes and decline in lung function.
- Patients with the BclI GG genotype showed a more pronounced deterioration in lung function.
- The study included a cohort of 255 young patients with cystic fibrosis.
Takeaway
This study found that a specific gene variation can affect how cystic fibrosis patients respond to treatment and how their lung function changes over time.
Methodology
The study evaluated the association between four GR gene polymorphisms and disease progression in a cohort of 255 young patients with cystic fibrosis using multivariable analysis.
Potential Biases
Potential bias due to retrospective data collection and variability in treatment adherence among patients.
Limitations
The study's retrospective design and reliance on medical records may introduce bias, and the population size, while adequate, requires replication in larger cohorts.
Participant Demographics
The mean age at enrollment was 11.1 years, with 53% being F508del homozygous and 36% compound heterozygous.
Statistical Information
P-Value
0.02 for FEV1 decline, 0.04 for FVC decline
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website